The role of melatonin in mood disorders

Abstract: Melatonin (N-acetyl-5-methoxytryptamine) has been discovered as a hormone secreted by the pineal gland, even though it is also synthesized in various other organs, tissues, and cells. The circadian rhythm of melatonin is often used as an indicator phase position since it is a well-defined, high-amplitude rhythm controlled by the hypothalamic suprachiasmatic nuclei. Melatonin production is controlled by this endogenous circadian timing system. It peaks during the night and is suppressed by daylight. Mood spectrum disorders, including bipolar disorder (BD), major depressive disorder (MDD), and seasonal affective disorder (SAD), have been observed to be accompanied by circadian dysregulation as well as dysregulation in melatonin secretion. Simultaneously, it has also been documented that disruptions in circadian rhythms, including the sleep/wake cycle, though environmental means can produce mood-related problems in vulnerable individuals. These findings suggested that altered circadian rhythms might be biological markers of these disorders. As melatonin is considered a chronobiotic factor, ie, able to entrain the circadian rhythms of several biological functions (eg, activity/rest, sleep/wake, body temperature, endocrine rhythms, etc), its use may provide a new therapeutic approach for the treatment of affective disorders. However, the available evidence is controversial. This review summarizes the data published so far about reliable evidence on the role of melatonin in affective disorders.

Keywords: melatonin, melatonergic system, mood disorders, depression, seasonal affective disorder, bipolar disorder

Introduction

Melatonin (chemically, N-acetyl-5-methoxytryptamine) is an indolamine hormone isolated and characterized, in 1958, by the dermatologist Aaron Lerner who found, in extracts of bovine pineal glands, an amphibian skin-lighting factor, subsequently called melatonin due to its ability of inducing contraction of stellate amphibian melanophores.1

It is mainly synthetized, as a derivative of the amino acid tryptophan, by the parenchymal cells of the pineal gland,2 and then rapidly secreted into the blood vascular system and cerebrospinal fluid. Secondary sources are retina, gut, skin, platelets, bone marrow, and other structures.3–8 The synthesis involves three enzymatic steps. The first is the metabolism of L-tryptophan to serotonin (or 5-hydroxytryptamine). The second step is the N-acetylation by the enzyme serotonin N-acetyltransferase (SNAT) to yield N-acetylsertotonin. The physiological regulation of SNAT, with its sharp increase in activity at night, is considered the major regulatory step in melatonin synthesis.9,10 The final step of the synthesis pathway is the conversion of N-acetylsertotonin to melatonin by the action of the enzyme hydroxyindole-O-methyltransferase (HIOMT).
The day/night changes of HIOMT are less prominent; however, HIOMT gene transcription has also been described to have a day/night rhythm.11

Melatonin is secreted by the pineal gland by simple diffusion. Its lipophilicity contributes to its easy passive diffusion across cell membranes as well as through cell layers.12 About 60%–70% of melatonin in the plasma is bound to albumin.13,14 Its plasma half-life after intravenous infusion is about 30 minutes,15 but a biphasic elimination pattern with half-lives of about 3 and 45 minutes has also been observed following oral administration.16 The circulating melatonin is rapidly converted to 6-hydroxymelatonin in the liver, which clears 92%–97% of circulating melatonin in a single pass. The 6-hydroxymelatonin is then conjugated and excreted in urine. The sulfate derivative of 6-hydroxymelatonin accounts for 50%–80% of the excreted melatonin and the glucuronide derivative for 5%–30%. The remaining melatonin is excreted either unchanged (less than 1%), as 5-methoxyindoleacetic acid (0.5%), or as the nonindolic metabolite N-acetyl-5-methoxykynurenamine (15%).17,18

The rhythm of melatonin synthesis and secretion is entrained to a circadian period largely by the environmental alteration of light and darkness.19 Light is perceived by a subtype of retinal ganglion cells, which transmits photic stimuli to the suprachiasmatic nucleus (SCN) of the hypothalamus through the retino-hypothalamic tract.20–22 The SCN, in turn, conveys the signal to the pineal gland through a multisynaptic pathway and is responsible of the circadian rhythm of melatonin, which is characterized by a gradual rise suddenly after the time of lights off and by a peak at the middle of the night (around 3:00–04:00 am), with a subsequent slow decline during the second part of the night.19 This remarkable diurnal variation is also determined by the secretion of norepinephrine, released at night from postganglionic sympathetic nerves that innervate the pineal gland. The stimulation of the sympathetic nerves on the pineal gland is strictly connected to the environmental light–dark cycle.2,13 Furthermore, melatonin synthesis depends upon tryptophan availability23 and other nutritional factors such as folate status and vitamin B6, a coenzyme in tryptophan decarboxylation which is able to stimulate melatonin production.24–26

Melatonin acts through the activation of specific receptors which are called MT1 and MT2.27 They belong to the superfamily of seven-transmembrane superfamily G protein-coupled receptors. Their activation leads to the inhibition of the adenylate cyclase with subsequent decrease of intracellular cyclic adenosine monophosphate which, in turn, provokes the inhibition of protein kinase A and of CREB protein phosphorylation.28,29 MT2 receptor additionally inhibits the soluble guanylyl cyclase pathway.30,31 However, depending on the tissue and species, melatonin receptor activation can elicit a variety of second messenger cascades.27 In fact, MT1 and MT2 were also found in many other tissues (eg, retina, ovary, testis, mammary gland, liver, kidney, skin, immune system, duodenum, adipocytes, myometrium, etc).3–8

Melatonin levels can be assessed by measuring its levels in blood, saliva, and by measuring its urinary metabolite, the 6-sulfatoxymelatonin (aMT6s). The most commonly used circadian melatonin phase marker is the dim light melatonin onset (DLMO).32 DLMO marks the time of the beginning of one’s biological night and is also useful for assessing circadian misalignment and for phase typing. It is defined as the interpolated clock time at which the ascending phase of melatonin reaches 20 pg/mL. Some authors use a cut-off of a smaller value, such as 10 pg/mL or even lower.33 The phase angle difference (PAD) between DLMO and midsleep can be used as a marker for internal circadian alignment and may also be used for phase typing.34

Affective disorders such as major depressive disorder (MDD), bipolar disorder (BD), and seasonal affective disorder (SAD) are accompanied by circadian function dysregulations, including changes in biochemical (melatonin and cortisol profiles), actigraphic (sleep/wake patterns), and dimensional (chronotypes) circadian markers, which can occur during acute mood episodes as well as during euthymic periods.35–37

In fact, in addition to the classical monoaminergic hypotheses that have been long proposed to explain the pathophysiology of mood spectrum disorders, a strong association between circadian rhythms, dysregulation in melatonin secretion, and mood regulation has been suggested in the light of several preclinical and clinical findings.38–47

There is good evidence that melatonin contributes to the entrainment of the circadian rhythms of several biological functions, including activity/rest, sleep/wake, body temperature, heart rate, liver and kidney function, and endocrine rhythms.45,48–50 Moreover, it is well documented that exogenous melatonin shows a good clinical response for reducing difficulties of falling asleep or improving symptoms associated with poorly coupled circadian rhythms, which may be present in the symptomatology of mood disorders.51,52 According to these findings, affective disorders caused by circadian dysfunction may be theoretically treatable by manipulating the circadian system using melatonin administration.46 However, there are contradictory data on its efficacy in the treatment of affective disorders.
The present review aims to provide an overview of data published so far about the potential role of melatonin in affective disorders.

Methodology/search strategy
PubMed/Medline databases were searched by using the following sets of keywords: ([melatonin] AND [bipolar disorder OR major depression OR seasonal affective disorder OR affective disorder OR mania]). A selectively targeted literature review of English language studies was carried out. No time restrictions were placed on the electronic search covering the period up to January 2015. Secondary searches were performed using the reference list of identified papers/documents. To be included in the review, studies were required to investigate the circadian melatonin pattern (eg, its alterations) in the affective disorders (BD, MMD, or SAD). All studies not focusing on these specific topics were properly excluded, including animal studies; studies referring to melatonergic drugs; studies on population without a diagnosis of an affective disorder; studies on pregnant women, healthy subjects, or subjects affected with comorbid organic pathologies (eg, neuromuscular diseases); studies focusing on jet lag, sleep disorders, or bright light therapy. The search was performed independently by the authors. Data were compared and discrepancies were settled, if needed. Finally, data were then ranked in three macrocategories, eg, those pertaining to role of melatonin in MMD, those referring to BD, and, finally, those regarding SAD.

With the initial set of keywords, some 1,300 studies were identified. Of these, 448 were excluded because they were either focused on preclinical/animal research (328) or were not in English language (120); whilst 674 were did not meet the inclusion criteria. Out of the remaining 181 studies, 101 were excluded because they were duplicated or were not consistent with the aims of this review, leaving a total of 80 documents to be considered for inclusion in this review. A total of 49 studies were deemed of interest for MMD, of which 30 focused on circadian dysregulation in MDD (Table 1); 16 studies referred to BD, of which 8 referred to circadian dysregulation in BD (Table 2); and, finally, 15 focused on SAD, of which 9 focused on circadian dysregulation in SAD (Table 3).

The role of melatonin in major depressive disorder
Alteration of circadian rhythms in major depression, particularly unipolar depression, were first described more than 30 years ago. Several studies have later identified alterations in the melatonin secretory pattern in depression as well as in dysthymia; firstly, this suggests that, in MDD, the endogenous circadian pacemaker is set abnormally early (misaligned) with respect to the timing of sleep. However, subsequent studies have not consistently found that the endogenous circadian pacemaker is set either abnormally early (phase advanced) or late (phase delayed) in individuals with MDD and that there is a large range of circadian dysregulation. In particular, the most consistent findings have been lower nocturnal melatonin levels, phase advance of melatonin onset or peak, a delay in the peak, onset, or offset of melatonin secretion, as well as a longer duration of aMT6s excretion.

According to these findings, therapeutic strategies aimed at resynchronizing the circadian clock of depressed patients have been developed, such as sleep deprivation and light therapy, even though there are contradictory findings. Furthermore, it was proposed to be a “low-melatonin syndrome.” However, further studies reported that only a subgroup of depressive patients had lower melatonin levels compared to healthy subjects. These patients showed an abnormal response to dexamethasone suppression test (DST).

Conversely, other studies described increased levels in melatonin concentrations in depressive patients. Therefore, it has been hypothesized that different melatonin patterns may reflect different subcategories of MDD and that melatonin levels may be also related to alterations in serotonin and norepinephrine levels.

Furthermore, recent studies have found a relationship between severity of unipolar depression and circadian misalignment. In addition, clinical evidence that antidepressant drugs as well as mood stabilizers affect the rhythmicity of the melatonin secretion has pointed to the possibility of the involvement of melatonin in the pathophysiology of MDD.

Finally, other studies have not demonstrated significant differences in melatonin pattern nor decrease/phase shift in MDD patients compared with healthy subjects, only reporting a nonsignificant trend toward higher melatonin levels in MDD patients compared with healthy subjects.

Although preclinical and some clinical data supported melatonin antidepressant potentials in rodent models, melatonin seems to lack antidepressant activity in humans. In fact, the few studies administering melatonin to depressed patients found improvement of sleep disturbances, but no effect on depressive symptoms nor an enhancing effect of existing antidepressant therapies in patients with depression.
Melatonin circadian pattern in MDD: summary of the findings from literature

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mendlewicz et al</td>
<td>Significant lower nocturnal M levels in MDD</td>
</tr>
<tr>
<td>Wetterberg</td>
<td>Significant lower nocturnal M levels in MDD</td>
</tr>
<tr>
<td>Clausrat et al</td>
<td>Significant lower nocturnal M levels in MDD</td>
</tr>
<tr>
<td>Parry and Newton</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Beck-Friis et al</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Nair et al</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Brown et al</td>
<td>Significant lower nocturnal M levels in MDD (melancholic subgroup) compared to HC</td>
</tr>
<tr>
<td>McIntyre et al</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Frazer et al</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>McIntyre et al</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Fountoulakis et al</td>
<td>Significant lower nocturnal M levels in melancholic depressed patients compared to atypical and undifferentiated depressed</td>
</tr>
<tr>
<td>Paparrigopoulos</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Wehr et al</td>
<td>Phase advance of M onset in MDD</td>
</tr>
<tr>
<td>Buckley and Schatzberg</td>
<td>Phase advance in MDD compared to HC</td>
</tr>
<tr>
<td>Khaleghipour et al</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Voderholzer et al</td>
<td>No difference between night time levels of M in MDD and HC</td>
</tr>
<tr>
<td>Crasson et al</td>
<td>Significant lower nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Wehr and Goodwin</td>
<td>Phase advance of M onset in MDD</td>
</tr>
<tr>
<td>Tuunainen et al</td>
<td>Correlation between delayed offset of aMT6s excretion and MDD</td>
</tr>
<tr>
<td>Rubin et al</td>
<td>Significant higher nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Emens et al</td>
<td>Phase delay of M onset is correlated with depression severity</td>
</tr>
<tr>
<td>Parry et al</td>
<td>Increased M secretion into the morning in MDD compared to HC</td>
</tr>
<tr>
<td>Hasler et al</td>
<td>Phase delay in MDD compared to HC</td>
</tr>
<tr>
<td>Robillard et al</td>
<td>No significant group differences in the PAD between MDD and HC</td>
</tr>
<tr>
<td>Rahmen et al</td>
<td>A greater heterogeneity in PAD among MDD patients</td>
</tr>
<tr>
<td>Rahman et al</td>
<td>No significant group difference in the PAD between MDD and BD</td>
</tr>
<tr>
<td>Beck-Friis et al</td>
<td>Phase delay of M onset in young people with MDD and BD</td>
</tr>
<tr>
<td>Carvalho et al</td>
<td>Low M secretion may desynchronize endogenous rhythms allowing subsyndromal MDD</td>
</tr>
<tr>
<td>Carvalho et al</td>
<td>Significant lower nocturnal M levels in MDD and BD compared to HC</td>
</tr>
<tr>
<td>Sekula et al</td>
<td>No significant differences in M secretion between MDD and HC</td>
</tr>
<tr>
<td>Sekula et al</td>
<td>No decrease nor a phase shift in MDD</td>
</tr>
<tr>
<td>Shafi et al</td>
<td>Significant higher nocturnal M levels in MDD compared to HC</td>
</tr>
<tr>
<td>Thompson et al</td>
<td>Only a nonsignificant trend toward higher M levels in MDD</td>
</tr>
</tbody>
</table>

Abbreviations: PAD, phase angle difference; MDD, major depressive disorder; BD, bipolar disorder; HC, healthy controls; M, melatonin; aMT6s, 6-sulfatoxymelatonin.

treatment-resistant depression. To date, according to a recent metaanalysis, there is no clear evidence of a therapeutic or prophylactic effect of melatonin in MDD.

The role of melatonin in bipolar disorder

Chronobiological models have contributed to a better understanding of the pathophysiology of BD. Circadian function dysregulations, changes in the timing, and phase position are associated with BD, including melatonin secretion and sleep/wake patterns. In particular, it has been noted that in manic patients phase alterations such as phase advance in melatonin levels and delayed peak melatonin secretion are accompanied by lower melatonin levels.

Although melatonin has proved to be a reliable marker of circadian phase, few studies have focused on this measure in...
BD and have yielded contradictory findings. Some studies reported phase disturbances in the melatonin secretion in BD whilst others reported no phase variations. Subjects affected by BD have demonstrated significantly lower peak nocturnal melatonin levels when compared to healthy controls and unipolar depressive patients. Furthermore, both euthymic and acutely ill bipolar patients have also demonstrated a hypersensitive pineal response to ocular light exposure when compared to controls. Some studies, which specifically evaluated patients affected with BD, reported a reduction in melatonin secretion during the depressed phase and an increase in the manic phase of the illness whilst a restoration during the remission of symptomatology. These findings suggested that melatonin levels in BD might be more a “trait marker” rather than a “state marker”.

It remains unclear whether these findings indicate a primary dysfunction of the circadian timing system or whether they may be secondary to sleep disturbances, a prominent characteristic in BD.

Sleep disturbance is a hallmark of BD. Sleep disturbances have been associated with a worse course of illness, increased symptom severity, and impairments in functioning and quality of life. In fact, patients affected with BD exhibit marked reduction in sleep during the night prior to switching from depressive to manic phase of the illness. A case report evaluation efficacy of melatonin administration in a young refractory BD patient showed relief from insomnia and manic episode. An open-label study reported that melatonin administration was associated with increased sleep duration as well as decrease in manic symptoms. A recent prospective naturalistic study reported sleep and mood improvement after administration of exogenous melatonin. Melatonin did not have a beneficial effect in another study conducted on bipolar patients.

The role of melatonin in seasonal affective disorder or winter depression

The role of melatonin in the seasonal changes in physiology and behavior of various photoperiodic species has been extensively documented. In fact, the seasonal alterations of the natural photoperiod at high latitudes have a repercussion on melatonin secretion, and the melatonin rhythm is delayed during winter compared with the summer. Some studies reported that these alterations in melatonin secretion were also found in healthy subjects.

SAD or winter depression affects upward of 10% of the population at temperate latitudes. It is characterized by

Table 2 Melatonin circadian pattern in BD: summary of the findings from literature

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robillard et al</td>
<td>- No significant group difference in the PAD between MDD and BD</td>
</tr>
<tr>
<td>Lam et al</td>
<td>- Longer phase delay of M onset in BD compared to MDD</td>
</tr>
<tr>
<td>Beck-Friis et al</td>
<td>- Significant lower nocturnal M levels in BD compared to HC and MDD</td>
</tr>
<tr>
<td>Lewy et al</td>
<td>- Significant lower nocturnal M levels in BD during depressed phase</td>
</tr>
<tr>
<td></td>
<td>- Significant higher nocturnal M levels in BD during manic phase</td>
</tr>
<tr>
<td>Kennedy et al</td>
<td>- Phase advance of M onset in BD</td>
</tr>
<tr>
<td></td>
<td>- Significant lower nocturnal M levels in BD during depressed phase</td>
</tr>
<tr>
<td></td>
<td>- Significant higher nocturnal M levels in BD during manic phase</td>
</tr>
<tr>
<td></td>
<td>- Phase advance of M onset in BD</td>
</tr>
<tr>
<td>Kennedy et al</td>
<td>- No significant differences in M secretion among several BD states</td>
</tr>
<tr>
<td>Souetre et al</td>
<td>- Significant lower nocturnal M levels in BD compared to HC</td>
</tr>
<tr>
<td></td>
<td>- No significant differences in aMT6s levels between BD and HC</td>
</tr>
<tr>
<td>Lewys et al</td>
<td>- Significant lower nocturnal M levels in BD during depressed phase</td>
</tr>
<tr>
<td></td>
<td>- Significant higher nocturnal M levels in BD during manic phase</td>
</tr>
<tr>
<td></td>
<td>- Restoration of M levels during the remission of BD</td>
</tr>
<tr>
<td></td>
<td>- Significant lower nocturnal M levels in BD during depressed phase</td>
</tr>
<tr>
<td></td>
<td>- Significant higher nocturnal M levels in BD during manic phase</td>
</tr>
</tbody>
</table>

Table 3 Melatonin circadian pattern in SAD: summary of the findings from literature

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lewy et al</td>
<td>- Most SAD are phase-delayed</td>
</tr>
<tr>
<td></td>
<td>- A SAD subgroup is phase-advanced</td>
</tr>
<tr>
<td>Wehr et al</td>
<td>- Phase delay of M onset during the winter in SAD</td>
</tr>
<tr>
<td></td>
<td>- Phase delay of M onset during the winter rather than summer in SAD</td>
</tr>
<tr>
<td>Kárádóttir and Axelsson</td>
<td>- Phase delay of M offset in SAD compared to HC</td>
</tr>
<tr>
<td>Danilenko et al</td>
<td>- Higher M levels during winter in SAD compared to HC</td>
</tr>
<tr>
<td>Lewy et al</td>
<td>- Phase delay of M onset during the winter in SAD</td>
</tr>
<tr>
<td>Terman et al</td>
<td>- Phase delay of M onset in SAD</td>
</tr>
<tr>
<td>Dahl et al</td>
<td>- Phase delay of M onset in SAD compared to HC</td>
</tr>
<tr>
<td>Checkley et al</td>
<td>- No significant differences in circadian rhythms between SAD and HC</td>
</tr>
</tbody>
</table>

Abbreviations: SAD, seasonal affective disorder; M, melatonin; HC, healthy controls.
recurrent depressive episodes during the short photoperiod (usually, fall/winter months) and euthymia during spring/summer periods. Individuals with SAD are negatively affected by the shorter days and later sunrise of the winter months and develop a syndrome characterized by carbohydrate craving, lethargy, fatigue, and sadness.36

Changes in duration and/or phase of melatonin secretion during this period (the so called “phase shift hypothesis”)140 were hypothesized to play a role in the pathogenesis of SAD and prompted its treatment with phototherapy.141 In patients affected with SAD, the most prominent marker of seasonal variations may be represented by the change in the melatonin offset.142 In fact, it seems that these patients generate a biological signal indicative of the seasonal change, like photoperiodic animals do.142,143 In addition, several studies have documented higher daytime melatonin levels during the winter season in patients affected with SAD compared to healthy controls142–144 and phase delay of circadian rhythms during the winter months.141,142,145–150 However, other studies underlined no significant differences in circadian rhythms between SAD patients compared with the healthy controls evaluated.151

Although phototherapy is an effective treatment of SAD, because it induces a phase advancing141,144,149,150 of circadian rhythms by correcting the PAd between circadian and sleep–wake schedules, the beneficial effect of this treatment does not seem to be supported by changes in melatonin.121,143,145,146,152 Studies focusing on efficacy of melatonin administration in SAD patients showed contradictory findings.153 In fact, although some studies reported a significant improvement of mood symptomatology,148,154 no significant differences were demonstrated after administrating exogenous melatonin compared with the placebo group.155,156 However, the phase shift hypothesis supports its efficacy in the treatment of seasonal circadian dysregulation in SAD patients, due to its capability to cause phase advances (when taken during evening) or phase delays (when taken during morning).34,140

**Current melatonergic drugs on the market**

In the last years, advances in medicinal chemistry led to the discovery of compounds that are specific and selective agonists and antagonists for melatonin receptors. Amongst them, some melatonergic drugs are on the market and are currently used in the clinical practice whilst others are also under evaluation (Table 4).157–175

For a more comprehensive review see Carocci et al.176

**Discussion and summary**

The present narrative review aimed to summarize available evidence on circadian melatonin dysregulation in affective disorders. However, the findings provided here include a large number of contradictory data. Most of the studies

<table>
<thead>
<tr>
<th>Melatonergic drug</th>
<th>Trade names</th>
<th>Approval</th>
<th>Pharmacological actions</th>
<th>Chronobiotic effects</th>
<th>Clinical effects</th>
<th>Sleep</th>
<th>Mood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agomelatine (Servier)</td>
<td>Valdoxan®</td>
<td>EMA (2009)</td>
<td>MT1/MT2 nonselective agonist S-HT-2a antagonist</td>
<td>Phase advance and entrains circadian system</td>
<td>Significant benefits in MDD</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Melior®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Significant benefits in MDD and SAD</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Thyminan®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Ramelteon (Takeda Pharmaceutical Company)</td>
<td>Rozerem®</td>
<td>FDA (2005)</td>
<td>MT1/MT2 nonselective agonist S-HT-2a antagonist</td>
<td>Phase advance</td>
<td>Significant benefits in insomnia</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Tasimelteon (VEC-162; Vanda Pharmaceuticals)</td>
<td>Hetioz®</td>
<td>FDA (2014)</td>
<td>MT1/MT2 nonselective agonist</td>
<td>Phase advance and phase delay</td>
<td>Significant benefits in non-24-hour sleep–wake disorder</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>TIK-301 (PD-673S, LY-156, 73S; Tikvah Pharmaceuticals)</td>
<td></td>
<td></td>
<td></td>
<td>Promotes phase advance</td>
<td>Significant benefits in insomnia</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>UCM765</td>
<td></td>
<td></td>
<td>MT2 selective partial agonist</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>IIK7</td>
<td></td>
<td></td>
<td>MT1/MT2 full agonist</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>UCM793</td>
<td></td>
<td></td>
<td>MT1/MT2 nonselective agonist</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>UCM924</td>
<td></td>
<td></td>
<td>MT2 selective partial agonist</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Neu-P11 (Neurim Pharmaceuticals Ltd)</td>
<td></td>
<td></td>
<td>MT1/MT2 nonselective agonist</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Abbreviations:** EMA, European Medicines Agency; MT, melatonin receptor; MDD, major depressive disorder; SAD, seasonal affective disorder; N/A, not available; FDA, US Food and Drug Administration.
retrieved present a greater heterogeneity in sample number and characteristics and in inclusion and exclusion criteria. For example, the extreme variability in melatonin pattern in MDD may suggest, both, the existence of different subgroups of depressive patients (eg, with different degrees of severity or a seasonal vulnerability) and an inaccurate initial selection of MDD patients (eg, an inclusion of subsyndromal BD or SAD patients). In addition, it could be argued that most data may be influenced by the choice of the age of the sample. In fact, a different circadian alignment according to the age has been reported. Another limitation may be represented by the small sample size used in most studies analyzed here, which may limit the generalizability of data.

SAD and mood disturbances (MDD and BD) caused by circadian malfunction are theoretically treatable by manipulating the circadian system using chronobiologic drugs, chronotherapy, or bright light therapy. There is no doubt that melatonin has chronobiologic properties as well as the ability to induce transient sleepiness or sleep. However, very few and contradictory evidence exist about its role in mood disorders and its potentiality in the treatment of these disorders. In fact, although melatonin appears to be well tolerated and is an effective treatment for a number of sleep disorders related to circadian rhythm disturbance, there is no conclusive confirmation about its efficacy in the treatment of mood disorders. However, due to the well-documented alterations in circadian rhythms and in melatonin secretion in mood disorders, more effective melatonin analogs (eg, agomelatine, tasimelteon, etc) have been developed and studied in order to obtain a reliable and effective drug for the treatment of mood disorders.

Further studies are necessary in order to better characterize the effect of exogenous melatonin and novel melatonergic drugs on the circadian system of MDD, BD, and SAD patients.

Acknowledgments
This paper is dedicated to Professor Venkataramanjam Srinivasan (1946–2014), a talented, smart, and intelligent researcher whose premature death has left a great void in contemporary neuroscience and melatonin research. All authors have contributed to this review with equal efforts.

Disclosure
This manuscript was entirely funded by the authors, and no pharmaceutical companies were informed of or involved in the review. The authors have no potential conflicts of interest that are directly relevant to the contents of the manuscript.

References


De Berardis et al


